Bueno M R, Daneri A, Armendáriz-Borunda J
Institute of Molecular Biology in Medicine, CUCS, University of Guadalajara, Jal, Mexico.
J Hepatol. 2000 Dec;33(6):915-25. doi: 10.1016/s0168-8278(00)80123-3.
BACKGROUND/AIM: Several drugs have been tested for the treatment of hepatic cirrhosis induced by various etiologic agents. Although interferon (IFN)alpha-2a has mostly been used to treat viral hepatitis, its anti-fibrogenic properties remain to be established.
An experimental model of cholestasis-induced cirrhosis was used to test the effect of IFNalpha-2a. Cirrhosis was induced in rats via ligation of the common bile duct. IFNalpha-2a (100,000 IU/rat, s.c.) was administered daily throughout the experiment. Collagens and TIMP-1 mRNA transcripts were determined by semi-quantitative reverse transcriptase-polymerase chain reaction in liver tissue samples. Activity of metalloproteases (MMPs) was measured using gelatin (denatured collagen) as substrate and the specific size of the enzymes was estimated by zymograms. Histology was performed using Sirius red as a specific stain for collagenous material, and computer-assisted morphometric analyses were carried out. A polyclonal mouse anti-plasminogen activator inhibitor (PAI-1) antibody was used to evaluate the distribution during treatment with IFNalpha-2a.
RESULTS/CONCLUSIONS: MMP-activity was up-regulated in bile duct ligated rats treated with IFNalpha-2a. MMP-activity in homogenates of total liver was minimal as compared with activity in non-parenchymal cells isolated from the same parental perfused liver, indicating a cryptic MMP activity which was completely abolished by EDTA and 1,10 phenanthroline. Three bands of gelatin degradation were detected by zymography, corresponding to 95, 75 and 65 kDa. IFNalpha-2a decreased PAI-1 immunoreactivity in liver tissue slices as well as biochemical activity in non-parenchymal cell extracts (3.3+/-0.08 vs 7.4+/-1.1 U/mg protein). Procollagen alpha1 (III) and alpha1 (IV) genes expression were also down-regulated 1.5 and 4-fold, respectively. Interestingly, TIMP-1 gene expression did not change. Functional hepatic tests: alanine aminotransferase, aspartate aminotransferase, bilirubins and alkaline phosphatase were significantly lower in IFNalpha-2a treated animals. Analysis of histology demonstrated that IFNalpha-2a promoted resolution of fibrosis and decreased bile duct proliferation.
背景/目的:已对多种药物进行了测试,用于治疗由各种病因引起的肝硬化。尽管α-2a干扰素大多用于治疗病毒性肝炎,但其抗纤维化特性仍有待确定。
使用胆汁淤积诱导的肝硬化实验模型来测试α-2a干扰素的效果。通过结扎胆总管在大鼠中诱导肝硬化。在整个实验过程中每天皮下注射α-2a干扰素(100,000 IU/大鼠)。通过半定量逆转录聚合酶链反应测定肝组织样本中的胶原蛋白和TIMP-1 mRNA转录本。使用明胶(变性胶原蛋白)作为底物测量金属蛋白酶(MMPs)的活性,并通过酶谱法估计酶的特定大小。使用天狼星红作为胶原蛋白材料的特异性染色剂进行组织学检查,并进行计算机辅助形态计量分析。使用多克隆小鼠抗纤溶酶原激活物抑制剂(PAI-1)抗体评估α-2a干扰素治疗期间的分布情况。
结果/结论:在用α-2a干扰素治疗的胆管结扎大鼠中,MMP活性上调。与从同一亲代灌注肝脏分离的非实质细胞中的活性相比,全肝匀浆中的MMP活性最小,表明存在一种隐蔽的MMP活性,其被EDTA和1,10菲咯啉完全消除。通过酶谱法检测到三条明胶降解带,分别对应于95、75和65 kDa。α-2a干扰素降低了肝组织切片中的PAI-1免疫反应性以及非实质细胞提取物中的生化活性(3.3±0.08对7.4±1.1 U/mg蛋白质)。前胶原α1(III)和α1(IV)基因表达也分别下调了1.5倍和4倍。有趣的是,TIMP-1基因表达没有变化。肝功能测试:在接受α-2a干扰素治疗的动物中,丙氨酸转氨酶、天冬氨酸转氨酶、胆红素和碱性磷酸酶显著降低。组织学分析表明,α-2a干扰素促进了纤维化的消退并减少了胆管增生。